-Gene editing technology and industry pattern at home and abroad

-Thalassemia and clinical treatment drug strategy (disease mechanism and gene editing technology strategy)

-Challenges of gene editing hematopoietic stem cell drug development

-Introduction of IND, the first gene editing hematopoietic stem cell drug in China

-Molecular mechanism of functional stability of FOXP3 + Treg

-Development and function of different subtypes of Treg in adipose tissue

-Prospect and prospect of Treg-related clinical immunotherapy

-Five CAR-T cell products targeting hematological tumors were approved for clinical application

-Challenges of CAR-T treatment

-Development strategy of new dual-target CAR technology

-R&D strategy of general CAR technology

-KRAS mutations are oncogenic and widely present in many cancer types .

-KRAS mutation are undruggable till recently.

-KRAS mutations are immunogenic.

-We developed TCR-T cell therpies targeting KRASG12V and G13D tumors 

-Based on QbD concept todesign the development process is an ideal commercial development path of cell therapy products.

-The whole process of quality control inessential for CAR T cells production.

-Fully enclosed and automated CAR T cell production is a priority for widespread application of CAR-T cell therapy.

-Experience of implementing ICH philosophy in facility construction and operation

- Considerations for technology/manufacturing process transfer within the ICH framework

-How should cost and quality be weighted?

-The current situation of the combination of automation, informationization and process of biopharmaceuticals

-Future development trend of biopharmaceutical digitalization

-Suggestions on the implementation path of biopharmaceutical digitalization

-Introduction to Rockwell Automation

-Requirement of biologics global commercialization

-Key consideration points 

-Case sharing of enabling international commercialization of "Chinese origin and made in China" biologics

-Industry Perspectives

-Considerations regarding downstream continuous manufacturing

-Summary and prospection

-Digitalization of material management

-The integration of material management and production automation

-Digitalization of the whole plant of biopharmaceuticals

- The third wave of new drug innovation represented by antibody drugs accelerates the research and development of new drugs, and the fourth wave of multi-specific and multi-functional drug innovation, including dual antibody and ADC technologies, will be one of the mainstream development in the next decade.

- New drug research and development depends on a full understanding of unmet needs, a deep understanding of the biological mechanism of diseases, a skillful mastery and application of new drug research and production technologies, and excellent clinical research and transformation capabilities, which is the key to finding the best and first drugs of the same kind, creating clinical value and benefiting the majority of patients.

- CRO and CDMO enterprises with end-to-end functional integration and super execution ability and in conformance to international standards can accelerate global innovation, reduce the cost of new drug research and development and production, and help solve the accessibility and affordability of drugs.

-Synergic inhibition on proliferation and differentiation of melanoma initiating cells with CSPG4-specific mAb and natural herbal extracts

-PD-1/PD-Ls co-stimulatory molecular pathway and tumor immune evasion

-Mechanisms underlying regulation of tumor immune evasion by natural herbal extracts mediated through PD-1 signaling